Telomerase activity in benign and malignant thyroid tumors.

Thyroid nodules are found in 5% to 10% of the population. While these nodules carry only a 5% to 10% risk of malignancy, tests that complement fine-needle aspiration (FNA) cytology in preoperative diagnosis and risk stratification are lacking. Telomerase is a ribonucleoprotein polymerase with activity found in many malignant tissues, but absent from most normal adult tissue. In this study, we have investigated telomerase activity in 24 thyroid tumors, 14 matched adjacent thyroid tissues, and 3 chronic thyroiditis tissue samples. Using a telomeric repeat amplification protocol (TRAP) assay on frozen tissue, telomerase activity was detected in 11 of 20 thyroid carcinomas, including 10 of 14 papillary carcinomas and a Hurthle cell carcinoma. Telomerase activity was not detected in 4 benign adenomas, 3 follicular carcinomas, or a single case each of medullary and anaplastic thyroid carcinoma. Telomerase activity was detected in 3 of 14 samples of adjacent thyroid tissue from patients with thyroid tumors. Interestingly, all 3 cases of adjacent thyroid tissue that tested positive had a moderate to marked degree of chronic inflammation. In addition, 3 of 3 samples from chronic thyroiditis specimens tested positive for telomerase activity. When tumor invasiveness (vascular and/or capsular) was compared with telomerase activity in papillary carcinomas, only 1 of 4 telomerase-negative tumors was invasive, while 6 of 10 of telomerase-positive tumors were invasive. Moreover, 6 of 7 invasive papillary carcinomas had telomerase activity. In summary, this is the first report of telomerase activity in thyroid tissue and nodules. This activity was detected in a large percentage of papillary thyroid carcinomas, but not benign adenomas, follicular carcinomas, or most normal thyroid tissue. Telomerase activity may also correlate with tumor invasiveness. Further studies will focus on larger numbers of tumors, metastatic tissue, and undifferentiated carcinomas, as well as application of this assay to products from fine-needle aspirates as a potential diagnostic and prognostic marker in thyroid neoplasms.

[1]  J. Shay,et al.  Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. , 1996, Cancer research.

[2]  V A Zakian,et al.  Telomeres: Beginning to Understand the End , 1995, Science.

[3]  J. Shay,et al.  Telomerase activity in human brain tumours , 1995, The Lancet.

[4]  J. Shay,et al.  Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. , 1995, Journal of immunology.

[5]  D. Broccoli,et al.  Telomerase activity in normal and malignant hematopoietic cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Shay,et al.  Telomerase activity in gastric cancer. , 1995, Cancer research.

[7]  D. Haber.  Telomeres, cancer, and immortality. , 1995, The New England journal of medicine.

[8]  V. Vasko,et al.  Fine-needle aspiration of thyroid follicular neoplasm: diagnostic use of thyroid peroxidase immunocytochemistry with monoclonal antibody 47. , 1994, Surgery.

[9]  L. Skoog,et al.  Thyroid peroxidase immunodetection as a tool to assist diagnosis of thyroid nodules on fine-needle aspiration biopsy. , 1994, European journal of endocrinology.

[10]  J. Hershman,et al.  Medical therapy for differentiated thyroid carcinoma. , 1994, Endocrine reviews.

[11]  M. Zou,et al.  Expression of thyrotrophin receptor gene in thyroid carcinoma is associated with a good prognosis , 1993, Clinical endocrinology.

[12]  H. Gharib,et al.  "Suspicious" thyroid cytologic findings: outcome in patients without immediate surgical treatment. , 1993, Mayo Clinic proceedings.

[13]  E. Mazzaferri,et al.  Management of a solitary thyroid nodule. , 1993, The New England journal of medicine.

[14]  E. Ridgway.  Clinical review 30: Clinician's evaluation of a solitary thyroid nodule. , 1992, The Journal of clinical endocrinology and metabolism.

[15]  G. Brabant,et al.  Human thyrotropin receptor gene: Expression in thyroid tumors and correlation to markers of thyroid differentiation and dedifferentiation , 1991, Molecular and Cellular Endocrinology.

[16]  P. Carayon,et al.  Immunohistochemical study of thyroid peroxidase in normal, hyperplastic, and neoplastic human thyroid tissues , 1991, Cancer.

[17]  J. Fagin,et al.  Expression of the myc cellular proto-oncogene in human thyroid tissue. , 1986, The Journal of clinical endocrinology and metabolism.

[18]  H. Battifora,et al.  Leu-Ml Antigen in Human Neoplasms: An Immunohistologic Study of 400 Cases , 1986, The American journal of surgical pathology.

[19]  S. Barsky,et al.  Diagnostic accuracy and use of aspiration biopsy in the management of thyroid nodules. , 1984, Archives of internal medicine.

[20]  Nitin R. Patel,et al.  A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables , 1983 .

[21]  D. S. Coffey,et al.  Telomerase activity: a prevalent marker of malignant human prostate tissue. , 1996, Cancer research.

[22]  M. Romano,et al.  Relationship between the level of c-myc mRNA and histologic aggressiveness in thyroid tumors. , 1993, Hormone research.

[23]  V. Ghali,et al.  Distribution of Leu-7 antigen (HNK-1) in thyroid tumors: its usefulness as a diagnostic marker for follicular and papillary carcinomas. , 1992, Human pathology.

[24]  M. Noguchi,et al.  Immunohistochemical demonstration of epidermal growth factor and c‐myc oncogene product in normal, benign and malignant thyroid tissues , 1991, Histopathology.